Teijin Pharma's abaloparatide now approved for osteoporosis

Japan’s Teijin Pharma has obtained manufacturing and sales approval from Japan’s Ministry of Health, Labor and Welfare (MHLW) for its Ostabalo (abaloparatide acetate) subcutaneous injection Cart 1.5mg. The newly-approved specification, which is for the treatment of osteoporosis, is expected to help promote bone formation in patients with high risk of bone fractures.

Ostabalo, which Teijin Pharma has positioned as a strategic product for robust market penetration, is a new osteoplasty accelerator that embodies the company’s extensive experience with treatments for bone and joint diseases.

The active ingredient in Ostabalo is abaloparatide acetate, a polypeptide containing a modification of one part of the 34 amino acid sequences from the N-terminus of human parathyroid hormone-related peptide. Abaloparatide acetate selectively stimulates RG-type parathyroid hormone type 1 receptors involved in bone metabolism. Abaloparatide acetate is subcutaneously administered by aqueous injection (cartridge) once daily (80μg) for adults for up to 18 months. With once-daily subcutaneous administration, it is expected to promote bone formation that exceeds bone resorption through an increase in bone mass, and to prevent bone fractures.